Drugs & money: Tailing top prescribers

| | Cardiovascular Business | Economics

ProPublica and NPR teamed up in an analysis of Medicare data to investigate prescribing habits for nebivolol (Bystolic), a treatment for hypertension. They reported that 17 of the top prescribers in 2010 accepted $283,450 in fees for promotional talks and more than $20,000 for meals from the drugmaker, Forest Laboratories. Most of the same names appeared again in results for 2011, the most recent year that data were available.

Top Medicare prescribers rake in speaking fees from drugmakers

Related Content

CMS proposes Medicare coverage for transcatheter tricuspid valve replacement
Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations
Cleerly’s momentum continues as AI specialists raise $106M
AI-powered ECG screening a cost-effective way to ID heart failure patients

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.